KIMBERLY LEE, ARNP
Nursing at 8 Ave, Seattle, WA

2010015, Jun 24, 2010

Jul 13, 2007

12/309311

Peter Hornbeck - Magnolia MA, US
Valerie Goss - Seabrook NH, US
Kimberly Lee - Seattle WA, US
Albrecht Moritz - Salem MA, US

G01N 33/573, G01N 33/53, C07K 16/00, C07K 7/06, C07K 7/08, C07K 14/00, C12N 5/071, C12N 5/16, C12N 5/18

435 74, 435 71, 5303871, 530328, 530327, 530326, 530325, 530324, 435326

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

2009026, Oct 22, 2009

Nov 29, 2006

12/086609

Roberto Polakiewicz - Lexington MA, US
Valerie Goss - Seabrook NH, US
Kimberly Lee - Seattle WA, US

G01N 33/573, C12Q 1/48, C07K 16/18, C12N 5/16, C12N 5/18

435 78, 435 15, 5303879, 435331

The invention discloses nearly 123 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, phosphatase/phospholipases, G proteins/GTPase activating proteins/guanine nucleotide exchange factors, cellular metabolism enzymes, DNA binding proteins, cytoskeletal proteins, cell cycle regulation proteins, proteases, RNA binding proteins, transcription proteins, translation initiation complex proteins, transferases, ubiquitin conjugating system proteins, vesicle proteins, actin binding proteins, apoptosis proteins, chemokine proteins, enzyme proteins extra cellular matrix proteins, helicases, hydrolases, immunoglobin superfamily proteins, inhibitor proteins, isomerases, ligases, lipid binding proteins, methyltransferases, motor proteins, receptor proteins, and chaperone proteins.

7999080, Aug 16, 2011

Jul 13, 2007

12/309310

Peter Hornbeck - Magnolia MA, US
Valerie Goss - Seabrook NH, US
Kimberly Lee - Seattle WA, US
Albrecht Moritz - Salem MA, US

Cell Signaling Technology, Inc. - Danvers MA

C07K 16/18

5303879

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

2010015, Jun 17, 2010

Jul 13, 2007

12/309312

Peter Hornbeck - Magnolia MA, US
Valerie Goss - Seabrook NH, US
Kimberly Lee - Seattle WA, US
Albrecht Moritz - Salem MA, US

CELL SIGNALING TECHNOLOGY, INC. - Danvers MA

G01N 33/53, C07K 16/18

435 71, 5303879

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

2009025, Oct 15, 2009

Feb 29, 2008

12/074199

Roberto Polakiewicz - Lexington MA, US
Ailan Guo - Burlington MA, US
Albrecht Moritz - Salem MA, US
Klarisa Rikova - Reading MA, US
Kimberly Lee - Seattle WA, US
Erik Spek - Cambridge MA, US
Yu Li - Andover MA, US
Charles Farnsworth - Concord MA, US

G01N 33/536, C07K 16/18

436536, 5303879

The invention discloses nearly 474 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Kinase, Adaptor/Scaffold proteins, Phosphatase, G protein Regulator/Guanine Nucleotide Exchange Factors/GTPase Activating Proteins, Cytoskeleton Proteins, DNA Binding Proteins, Phospholipase, Receptor Proteins, Enzymes, DNA Repair/Replication Proteins, Adhesion Proteins, and Proteases, as well as other protein types.

2009022, Sep 3, 2009

Feb 29, 2008

12/074214

Roberto Polakiewicz - Lexington MA, US
Valerie Goss - Seabrook NH, US
Albrecht Moritz - Salem MA, US
Kimberly Lee - Seattle WA, US

G01N 33/53, G01N 33/536, C07K 16/18, C12N 5/18

435 78, 436536, 5303877, 435330

The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins.

8466160, Jun 18, 2013

Dec 30, 2010

12/982490

Klarisa Rikova - Reading MA, US
Roberto Polakiewicz - Lexington MA, US
Ailan Guo - Lexington MA, US
Katherine Eleanor Crosby - Middleton MA, US
Qingfu Zeng - Hamilton MA, US
Kimberly A Lee - Seattle WA, US

Cell Signaling Technology, Inc. - Danvers MA

A01N 43/54, G01N 33/574, C12Q 1/68

514256, 435 723, 435 614, 514247

The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor.

2010012, May 27, 2010

Jul 27, 2007

12/309728

Roberto Polakewicz - Lexington MA, US
Charles Farnsworth - Concord MA, US
Ailan Guo - Burlington MA, US
Klarisa Rikova - Reading MA, US
Albrecht Moritz - Salem MA, US
Kimberly Lee - Seattle WA, US
Erik Spek - Cambridge MA, US

G01N 33/53, C07K 16/18

436501, 5303879

The invention discloses 351 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.